McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Last trade$1,092.35
Day change-$12.695 (-1.15%)
Day range$1,090.19 – $1,114.78
Volume284,394
Market cap$127.58B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$127.58B
Price / earnings
27.15×
Price / book
-32.27×
Price / sales
0.3×
EV / sales
0.31×
EV / EBITDA
16.73×
Profitability
Earnings per share
$40.71
Return on assets
5.09%
Return on equity
-118.87%
Dividend yield
0.31%
Liquidity and leverage
Debt / equity
-2.33×
Current ratio
0.9×
Quick ratio
0.52×
Cash ratio
0.09×
Cash flow
Price / cash flow
17×
Price / free cash flow
17.95×
Free cash flow
$7.11B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MCK, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$110.96B
$105.38B
$96.3B
$106.16B
$103.15B
$97.83B
$90.82B
$95.29B
Cost of revenue
$107B
$101.7B
$92.25B
$102.47B
$99.61B
$94.55B
$87.18B
$92.01B
Gross profit
$3.96B
$3.69B
$4.04B
$3.69B
$3.54B
$3.28B
$3.64B
$3.28B
Selling, general and administrative
$2.27B
$2.26B
$1.8B
$2.03B
$2.07B
$2.2B
$1.98B
$2.03B
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$2.35B
$2.37B
$1.89B
$2.07B
$2.14B
$2.24B
$2.05B
$2.06B
Operating income
$1.6B
$1.32B
$2.15B
$1.62B
$1.41B
$1.04B
$1.59B
$1.22B
Interest expense
-$105M
-$77M
-$61M
-$63M
-$74M
-$49M
-$45M
-$67M
Income before taxes
$1.56B
$1.31B
$2.13B
$1.63B
$1.4B
$1.05B
$1.52B
$1.23B
Income taxes
$266M
$276M
$270M
$380M
$232M
$220M
$209M
$298M
Net income
$1.3B
$1.03B
$1.86B
$1.25B
$1.16B
$831M
$1.31B
$928M
Net income attributable to common shareholders
$1.22B
$614M
$1.68B
$1.19B
$1.11B
$784M
$1.26B
$879M
EBITDA
$1.88B
$1.62B
$2.44B
$1.84B
$1.66B
$1.24B
$1.82B
$1.41B
Basic earnings per share
$10.47
$5.17
$13.81
$9.59
$8.95
$6.28
$10.12
$6.95
Diluted earnings per share
$10.44
$5.15
$13.64
$9.63
$8.92
$6.25
$9.97
$6.98
Recent news
Company coverage with links to the original publishers.
McKesson (MCK), a prescription drug distributor, has gained 12.6% over the past month, outperforming the S&P 500's -3.7% decline. The company has a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions. Current quarter EPS is expected at $10.79 (+15.5% YoY), with full-year earnings projected at $45.78 (+17.1% YoY). Revenue growth is forecasted at 8% for the current quarter and fiscal year. McKesson has consistently beaten consensus estimates and trades at a valuation discount to peers (Value Style Score: B).
The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.
McKesson (MCK) is highlighted as an attractive growth stock with a Zacks Growth Score of A and Zacks Rank #2 (Buy). The prescription drug distributor demonstrates strong fundamentals including projected 17% EPS growth (vs. 5.3% industry average), superior asset utilization ratio of 4.83, and positive earnings estimate revisions with a 3.2% upward surge over the past month.
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The prescription drug distributor's Zacks Consensus Estimate has increased 1.5% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade suggests potential near-term stock price appreciation based on improving business fundamentals.
McKesson reported $110.96 billion in revenue for Q3 2026, up 7.6% year-over-year and beating consensus estimates by 0.77%. EPS of $11.68 exceeded expectations of $10.69 by 9.26%. The company showed strong performance across most business segments, particularly in Oncology & Multispecialty and Prescription Technology Solutions, though Medical-Surgical Solutions operating profit fell short of estimates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.94 per share
Declared
Oct 20, 2026
Ex-dividend
Dec 1, 2026
Pay date
Jan 4, 2027
Ex-dividend
Amount / share
Pay date
Type
Sep 1, 2026
$0.94
Oct 1, 2026
recurring
Jun 1, 2026
$0.82
Jul 1, 2026
recurring
Mar 2, 2026
$0.82
Apr 1, 2026
recurring
Dec 1, 2025
$0.82
Jan 2, 2026
recurring
Sep 2, 2025
$0.82
Oct 1, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.